Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymetazoline + Fluticasone for Mild OSA with Nasal Congestion
NCT02630121Phase 4Recruiting
- Sponsor
- University of South Florida
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxymetazoline in obstructive sleep apnea (OSA) and nasal congestion (2 arms), sponsored by University of South Florida. Primary endpoint: Proportion of subjects with 50% reduction in Apnea Hypopnea Index at 2 weeks. Started Apr 2023; status: recruiting.
02
Drugs
oxymetazoline
03
Conditions
obstructive sleep apnea (OSA)nasal congestion
Beyond the preview
Go deeper on NCT02630121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630121.